Defining the Role of Intravenous Iron in The Treatment of Patients with Heart Failure with Reduced Ejection Fraction...

Area of Science:

• Cardiology
• Hematology

Background:

• Iron deficiency is prevalent in heart failure (HF), affecting up to 50% of patients, regardless of anemia.
• Current guidelines define iron deficiency using serum ferritin and transferrin saturation (TSAT) levels.
• Iron deficiency in HF is linked to adverse patient outcomes.

Purpose of the Study:

• To review the diagnosis, evaluation, and treatment of iron deficiency in heart failure patients.
• To present an approach for managing iron deficiency in patients with HF and reduced ejection fraction.
• To identify areas for clinical enhancement and future research in this field.

Main Methods:

• Comprehensive review of existing evidence on iron deficiency in heart failure.
• Analysis of diagnostic criteria and treatment strategies, including intravenous (IV) iron.
• Discussion of clinical management approaches for HF with reduced ejection fraction.

Main Results:

• Iron deficiency is common in HF and associated with poor outcomes.
• Intravenous (IV) iron is being evaluated as a therapeutic option.
• Guidelines provide definitions for iron deficiency based on ferritin and TSAT.

Conclusions:

• Iron deficiency is a significant comorbidity in heart failure that warrants attention.
• Intravenous (IV) iron therapy shows promise for improving outcomes in iron-deficient HF patients.
• Further research is needed to optimize the management of iron deficiency in HF.